PureTech, Seaport Advance GlyphAllo in Depression Therapy
BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...
BOSTON, Feb. 20, 2026 — Seaport Therapeutics announced new findings from a comprehensive meta-analysis examining how clinical trial design...
